{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:07:36Z","timestamp":1793210856198,"version":"4.5.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The demyelinating syndromes of the central nervous system (CNS) that occur in the context of systemic lupus erythematosus (SLE) may represent a manifestation of neuropsychiatric lupus (NPSLE) or an overlap of SLE and multiple sclerosis (MS). The differential diagnosis between the two entities has important clinical implications because the therapeutic management differs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To characterize CNS demyelinating syndromes in a large SLE cohort as neuropsychiatric SLE (NPSLE) or SLE-MS overlap using a multidisciplinary approach and existing diagnostic (for MS) and classification criteria (for SLE).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients from the \u201cAttikon\u201d lupus cohort (<jats:italic>n<\/jats:italic> = 707) were evaluated for demyelinating syndromes. Clinical, laboratory, and neuroimaging data were recorded for each patient. Following multidisciplinary evaluation and application of criteria, the demyelinating syndrome was attributed to either SLE or MS. Patients with transverse myelitis were not included in this study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 26 patients with demyelinating syndromes (3.7%). Of them, 12 were diagnosed as primary SLE-demyelination (46.2%) and 14 as overlap SLE-MS (53.8%). The two groups did not differ with respect to rheumatologic and neurologic manifestations or autoantibodies. SLE patients with demyelination manifested mild extra-CNS disease mainly involving joints and skin, while severe non-CNS manifestations were rare. However, these patients were less likely to have elevated IgG index (OR 0.055 95% CI: 0.008\u20130.40) and positive oligoclonal bands (OR 0.09 95% CI: 0.014\u20130.56), as well as brain lesions in the spinal cord, infratentorial, periventricular, and juxtacortical regions. A single brain region was affected in 9 patients with SLE-demyelination (75%), while all patients with MS-SLE had multiple affected brain regions. MS-SLE overlap was associated with an increased likelihood of neurologic relapses (OR 18.2, 95% CI: 1.76\u2013188), while SLE-demyelination patients were less likely to exhibit neurological deficits (EDSS &amp;gt;0) at the last follow-up visit (50 vs. 78.6% in SLE-MS, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Demyelination in the context of SLE follows a more benign course compared to a frank SLE-MS overlap. Extension of follow-up will ascertain whether patients with SLE-demyelination evolve to MS, or this is a <jats:italic>bona fide<\/jats:italic> NPSLE syndrome.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.889613","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T14:37:08Z","timestamp":1652279828000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Demyelinating Syndromes in Systemic Lupus Erythematosus: Data From the \u201cAttikon\u201d Lupus Cohort"],"prefix":"10.3389","volume":"13","author":[{"given":"Dionysis","family":"Nikolopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Kitsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda","family":"Papathanasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemin","family":"Kapsala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Garantziotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antigone","family":"Pieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ourania","family":"Gioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Voumvourakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Boumpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis","family":"Fanouriakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00296-009-1175-1","article-title":"Lupoid sclerosis","volume":"30","author":"Keiserman","year":"2010","journal-title":"Rheumatol Int."},{"key":"B2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO","volume":"42","year":"1999","journal-title":"Arthritis Rheum"},{"key":"B3","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.semarthrit.2013.11.007","article-title":"Coexistence of systemic lupus erythematosus and multiple sclerosis: prevalence, clinical characteristics, and natural history","volume":"43","author":"Fanouriakis","year":"2013","journal-title":"Semin Arthritis Rheum."},{"key":"B4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.berh.2013.07.010","article-title":"Demyelinating disease in SLE: is it multiple sclerosis or lupus?","volume":"27","author":"Magro Checa","year":"2013","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1093\/rheumatology\/keaa902","article-title":"Demyelination with autoimmune features: a distinct clinical entity? Results from a longitudinal cohort","volume":"60","author":"Nikolopoulos","year":"2021","journal-title":"Rheumatology."},{"key":"B6","first-page":"514","article-title":"Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the \u2018Attikon' cohort","volume-title":"Lupus","author":"Nikolopoulos","year":"2020"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e000394","DOI":"10.1136\/lupus-2020-000394","article-title":"Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease","volume":"7","author":"Nikolopoulos","year":"2020","journal-title":"Lupus Sci Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Nat Acad Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ndtplus\/sfp113","article-title":"Acute renal failure, systemic lupus erythematosus and thrombotic microangiopathy following treatment with beta-interferon for multiple sclerosis: case report and review of the literature","volume":"2","author":"Hansen","year":"2009","journal-title":"Clin Kidney J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.autrev.2017.01.011","article-title":"Demyelinating syndrome in SLE encompasses different subtypes: do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis","volume":"16","author":"Piga","year":"2017","journal-title":"Autoimmun Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/art.40356","article-title":"Understanding the antibody repertoire in neuropsychiatric systemic lupus erythematosus and neuromyelitis optica spectrum disorder: do they share common targets?","volume":"70","author":"Mader","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non-organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1352458511431077","article-title":"The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease","volume":"18","author":"Wingerchuk","year":"2012","journal-title":"Mult Scler."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1136\/annrheumdis-2017-211206","article-title":"Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece","volume":"76","author":"Gergianaki","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"The Lancet Neurology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S1474-4422(15)00393-2","article-title":"MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines","volume":"15","author":"Filippi","year":"2016","journal-title":"The Lancet Neurology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1177\/1352458519828601","article-title":"Iatrogenic CNS demyelination in the era of modern biologics","volume":"25","author":"Kumar","year":"2019","journal-title":"Mult Scler."},{"key":"B20","doi-asserted-by":"publisher","first-page":"102568","DOI":"10.1016\/j.msard.2020.102568","article-title":"CNS. demyelination during tofacitinib therapy: first report","volume":"46","author":"Massoud","year":"2020","journal-title":"Mult Scler Relat Disord."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.889613\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T14:37:11Z","timestamp":1652279831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.889613\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":20,"alternative-id":["10.3389\/fneur.2022.889613"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.889613","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]},"article-number":"889613"}}